S'abonner

Evolving viral and serological stages of Zika virus RNA-positive blood donors and estimation of incidence of infection during the 2016 Puerto Rican Zika epidemic: an observational cohort study - 26/11/20

Doi : 10.1016/S1473-3099(19)30706-6 
Phillip C Williamson, PhD a, , Brad J Biggerstaff, PhD b, Graham Simmons, PhD c, Mars Stone, PhD c, Val Winkelman, MS a, Gerardo Latoni, MD d, Jose Alsina, MS d, Sonia Bakkour, PhD c, Christina Newman, PhD e, Lisa L Pate, MD f, Susan A Galel, MD f, Steven Kleinman, ProfMD g, Michael P Busch, MD c
a Creative Testing Solutions, Tempe, AZ, USA 
b Centers for Disease Control and Prevention, Fort Collins, CO, USA 
c Vitalant Research Institute, San Francisco, CA, USA 
d Banco de Sangre Servicios Mutuos, Guaynabo, PR, USA 
e Department of Pathology and Laboratory Medicine, University of Wisconsin–Madison, Madison, WI, USA 
f Roche Molecular Systems, Pleasanton, CA, USA 
g Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada 

* Correspondence to: Dr Phillip C Williamson, Creative Testing Solutions, Tempe, AZ 85252, USA Creative Testing Solutions Tempe AZ 85252 USA

Summary

Background

Puerto Rico began screening blood donations for Zika virus RNA with nucleic acid amplification tests (NAATs) on April 3, 2016, because of an emerging Zika virus outbreak. We followed up positive donors to assess the dynamics of viral and serological markers during the early stages of Zika virus infection and update the estimate of infection incidence in the Puerto Rican population during the outbreak.

Methods

Blood donations from volunteer donors in Puerto Rico were screened for the presence of Zika virus RNA using the cobas Zika NAAT. Positive donations were further tested to confirm infection, estimate viral load, and identify Zika virus-specific IgM antibodies. Individuals with positive blood donations were invited to attend follow-up visits. Donations with confirmed infection (defined as detection of Zika virus RNA or IgM on additional testing of index or follow-up samples) were assessed for stage of infection according to Zika virus RNA detectability in simulated minipools, viral load, and Zika virus IgM status. A three-step process was used to estimate the mean duration of NAAT reactivity of Zika virus in human plasma from individuals identified pre-seroconversion with at least one follow up visit and to update the 2016 incidence estimate of Zika virus infection.

Findings

Between April 3 and Dec 31, 2016, 53 112 blood donations were screened for Zika virus, of which 351 tested positive, 339 had confirmed infections, and 319 could be staged. Compared with IgM-positive index donations (n=110), IgM-negative index donations (n=209) had higher mean viral loads (1·1 × 106 vs 8·3 × 104 international units per mL) and were more likely to be detected in simulated minipools (93% [n=194] vs 26% [n=29]). The proportions of donations with confirmed infections that had viral RNA detected only in individual-donation NAATs (ie, not in simulated minipools) and were IgM positive increased as the epidemic evolved. The estimated mean duration of NAAT detectability in the 140 donors included in the follow-up study was 11·70 days (95% CI 10·06–14·36). Applying this detection period to the observed proportion of donations that were confirmed NAAT positive yielded a Zika virus seasonal incidence estimate of 21·1% (95% CI 18·1–24·1); 768 101 infections in a population of 3 638 773 in 2016.

Interpretation

Characterisation of early Zika virus infection has implications for blood safety because infectivity of blood donations and utility of screening methods likely correlate with viral load and serological stage of infection. Our findings also have implications for diagnostic testing, public health surveillance, and epidemiology, and we estimate that around 21% of the Puerto Rican population was infected during the 2016 outbreak.

Funding

Biomedical Advanced Research and Development Authority, National Heart, Lung, and Blood Institute.

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 12

P. 1437-1445 - décembre 2020 Retour au numéro
Article précédent Article précédent
  • Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial
  • Shabir A Madhi, Eleonora AML Mutsaerts, Alane Izu, Welekazi Boyce, Sutika Bhikha, Benit T Ikulinda, Lisa Jose, Anthonet Koen, Amit J Nana, Andrew Moultrie, Lucy Roalfe, Adam Hunt, David Goldblatt, Clare L Cutland, Jeffrey R Dorfman
| Article suivant Article suivant
  • Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study
  • Mars Stone, Sonia Bakkour, Marion C Lanteri, Donald Brambilla, Graham Simmons, Roberta Bruhn, Zhanna Kaidarova, Tzong-Hae Lee, Jose Orlando Alsina, Phillip C Williamson, Susan A Galel, Lisa L Pate, Jeffrey M Linnen, Steve Kleinman, Michael P Busch, NHLBI Recipient Epidemiology Donor Evaluation Study REDS-III Program

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.